nodes	percent_of_prediction	percent_of_DWPC	metapath
Nebivolol—Allergic cutaneous angiitis—Methotrexate—esophageal cancer	0.00888	0.0634	CcSEcCtD
Nebivolol—Leukocytoclastic vasculitis—Methotrexate—esophageal cancer	0.00576	0.0411	CcSEcCtD
Nebivolol—Psoriasis—Methotrexate—esophageal cancer	0.00449	0.0321	CcSEcCtD
Nebivolol—Renal failure acute—Cisplatin—esophageal cancer	0.00405	0.0289	CcSEcCtD
Nebivolol—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.00359	0.00417	CbGpPWpGaD
Nebivolol—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00354	0.00411	CbGpPWpGaD
Nebivolol—HTR1A—G alpha (i) signalling events—SST—esophageal cancer	0.00352	0.00409	CbGpPWpGaD
Nebivolol—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00336	0.024	CcSEcCtD
Nebivolol—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.00334	0.00388	CbGpPWpGaD
Nebivolol—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.00329	0.00383	CbGpPWpGaD
Nebivolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00323	0.00376	CbGpPWpGaD
Nebivolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00316	0.00368	CbGpPWpGaD
Nebivolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00309	0.0036	CbGpPWpGaD
Nebivolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00301	0.00349	CbGpPWpGaD
Nebivolol—Renal failure acute—Capecitabine—esophageal cancer	0.00298	0.0213	CcSEcCtD
Nebivolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00294	0.00342	CbGpPWpGaD
Nebivolol—HTR1A—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.00293	0.00341	CbGpPWpGaD
Nebivolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00292	0.0034	CbGpPWpGaD
Nebivolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00287	0.00334	CbGpPWpGaD
Nebivolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00286	0.00333	CbGpPWpGaD
Nebivolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00285	0.00331	CbGpPWpGaD
Nebivolol—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00284	0.0203	CcSEcCtD
Nebivolol—Myocardial infarction—Cisplatin—esophageal cancer	0.00282	0.0202	CcSEcCtD
Nebivolol—ADRB1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00282	0.00328	CbGpPWpGaD
Nebivolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.0028	0.00325	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—GNG7—esophageal cancer	0.00279	0.00325	CbGpPWpGaD
Nebivolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00279	0.00324	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00276	0.0032	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—GNG7—esophageal cancer	0.00273	0.00318	CbGpPWpGaD
Nebivolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00273	0.00317	CbGpPWpGaD
Nebivolol—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.00272	0.00316	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00269	0.00313	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—GNG7—esophageal cancer	0.00267	0.00311	CbGpPWpGaD
Nebivolol—Bradycardia—Cisplatin—esophageal cancer	0.00263	0.0188	CcSEcCtD
Nebivolol—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.00259	0.00301	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00256	0.00297	CbGpPWpGaD
Nebivolol—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.00256	0.00297	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.0025	0.00291	CbGpPWpGaD
Nebivolol—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00248	0.0177	CcSEcCtD
Nebivolol—ADRB1—GPCR ligand binding—CXCL2—esophageal cancer	0.00246	0.00286	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00245	0.00284	CbGpPWpGaD
Nebivolol—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.00242	0.00282	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—CXCL2—esophageal cancer	0.00241	0.0028	CbGpPWpGaD
Nebivolol—Cardiac disorder—Cisplatin—esophageal cancer	0.0024	0.0171	CcSEcCtD
Nebivolol—HTR1A—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.00239	0.00278	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—CXCL2—esophageal cancer	0.00235	0.00274	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—GDI2—esophageal cancer	0.00234	0.00273	CbGpPWpGaD
Nebivolol—Bronchospasm—Capecitabine—esophageal cancer	0.00234	0.0167	CcSEcCtD
Nebivolol—ADRB2—Signaling Pathways—GDI2—esophageal cancer	0.00229	0.00267	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—ANXA1—esophageal cancer	0.00229	0.00266	CbGpPWpGaD
Nebivolol—Malnutrition—Cisplatin—esophageal cancer	0.00225	0.0161	CcSEcCtD
Nebivolol—HTR1A—Signaling Pathways—GDI2—esophageal cancer	0.00224	0.00261	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—ANXA1—esophageal cancer	0.00224	0.0026	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—SST—esophageal cancer	0.00223	0.00259	CbGpPWpGaD
Nebivolol—Renal failure acute—Methotrexate—esophageal cancer	0.00222	0.0159	CcSEcCtD
Nebivolol—HTR1A—GPCR ligand binding—ANXA1—esophageal cancer	0.00219	0.00255	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—SST—esophageal cancer	0.00218	0.00253	CbGpPWpGaD
Nebivolol—ADRB1—GPCR ligand binding—GHRL—esophageal cancer	0.00217	0.00252	CbGpPWpGaD
Nebivolol—HTR1A—GPCR ligand binding—SST—esophageal cancer	0.00213	0.00248	CbGpPWpGaD
Nebivolol—ADRB2—GPCR ligand binding—GHRL—esophageal cancer	0.00212	0.00247	CbGpPWpGaD
Nebivolol—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00209	0.0149	CcSEcCtD
Nebivolol—Myocardial infarction—Capecitabine—esophageal cancer	0.00208	0.0149	CcSEcCtD
Nebivolol—HTR1A—GPCR ligand binding—GHRL—esophageal cancer	0.00208	0.00241	CbGpPWpGaD
Nebivolol—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.00206	0.0024	CbGpPWpGaD
Nebivolol—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00203	0.00236	CbGpPWpGaD
Nebivolol—Bradycardia—Capecitabine—esophageal cancer	0.00194	0.0139	CcSEcCtD
Nebivolol—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.00194	0.00225	CbGpPWpGaD
Nebivolol—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00191	0.00222	CbGpPWpGaD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.0019	0.0136	CcSEcCtD
Nebivolol—Oedema peripheral—Capecitabine—esophageal cancer	0.00188	0.0134	CcSEcCtD
Nebivolol—ADRB1—GPCR downstream signaling—AKAP13—esophageal cancer	0.00182	0.00211	CbGpPWpGaD
Nebivolol—Nervous system disorder—Cisplatin—esophageal cancer	0.0018	0.0129	CcSEcCtD
Nebivolol—Thrombocytopenia—Cisplatin—esophageal cancer	0.0018	0.0128	CcSEcCtD
Nebivolol—Skin disorder—Cisplatin—esophageal cancer	0.00178	0.0127	CcSEcCtD
Nebivolol—ADRB2—GPCR downstream signaling—AKAP13—esophageal cancer	0.00178	0.00206	CbGpPWpGaD
Nebivolol—Cardiac disorder—Capecitabine—esophageal cancer	0.00177	0.0126	CcSEcCtD
Nebivolol—HTR1A—GPCR downstream signaling—AKAP13—esophageal cancer	0.00174	0.00202	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—KMT2D—esophageal cancer	0.0017	0.00197	CbGpPWpGaD
Nebivolol—Mental disorder—Capecitabine—esophageal cancer	0.00167	0.0119	CcSEcCtD
Nebivolol—ADRB1—GPCR downstream signaling—PDE4D—esophageal cancer	0.00166	0.00193	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—KMT2D—esophageal cancer	0.00166	0.00193	CbGpPWpGaD
Nebivolol—Malnutrition—Capecitabine—esophageal cancer	0.00166	0.0118	CcSEcCtD
Nebivolol—Paraesthesia—Cisplatin—esophageal cancer	0.00165	0.0118	CcSEcCtD
Nebivolol—ADRB1—Signaling by GPCR—AKAP13—esophageal cancer	0.00165	0.00192	CbGpPWpGaD
Nebivolol—Dyspnoea—Cisplatin—esophageal cancer	0.00164	0.0117	CcSEcCtD
Nebivolol—Erectile dysfunction—Methotrexate—esophageal cancer	0.00163	0.0117	CcSEcCtD
Nebivolol—HTR1A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.00163	0.0019	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—PDE4D—esophageal cancer	0.00162	0.00189	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—KMT2D—esophageal cancer	0.00162	0.00189	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—AKAP13—esophageal cancer	0.00161	0.00187	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—PDE4D—esophageal cancer	0.00159	0.00185	CbGpPWpGaD
Nebivolol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00159	0.0113	CcSEcCtD
Nebivolol—ADRB1—GPCR downstream signaling—GNG7—esophageal cancer	0.00158	0.00184	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—AKAP13—esophageal cancer	0.00158	0.00183	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—GNG7—esophageal cancer	0.00154	0.0018	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—ADCYAP1—esophageal cancer	0.00151	0.00176	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—GNG7—esophageal cancer	0.00151	0.00176	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—PDE4D—esophageal cancer	0.00151	0.00175	CbGpPWpGaD
Nebivolol—Vertigo—Capecitabine—esophageal cancer	0.00149	0.0106	CcSEcCtD
Nebivolol—Syncope—Capecitabine—esophageal cancer	0.00149	0.0106	CcSEcCtD
Nebivolol—ADRB2—Signaling Pathways—ADCYAP1—esophageal cancer	0.00148	0.00172	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—PDE4D—esophageal cancer	0.00147	0.00171	CbGpPWpGaD
Nebivolol—Loss of consciousness—Capecitabine—esophageal cancer	0.00146	0.0104	CcSEcCtD
Nebivolol—HTR1A—Signaling Pathways—ADCYAP1—esophageal cancer	0.00145	0.00168	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—PDE4D—esophageal cancer	0.00144	0.00168	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—GNG7—esophageal cancer	0.00143	0.00167	CbGpPWpGaD
Nebivolol—Chest pain—Capecitabine—esophageal cancer	0.00141	0.0101	CcSEcCtD
Nebivolol—ADRB2—Signaling by GPCR—GNG7—esophageal cancer	0.0014	0.00163	CbGpPWpGaD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.0014	0.01	CcSEcCtD
Nebivolol—ADRB1—GPCR downstream signaling—CXCL2—esophageal cancer	0.00139	0.00162	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—WWOX—esophageal cancer	0.00138	0.00161	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—GNG7—esophageal cancer	0.00137	0.00159	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—CXCL2—esophageal cancer	0.00136	0.00158	CbGpPWpGaD
Nebivolol—Hypersensitivity—Cisplatin—esophageal cancer	0.00135	0.00966	CcSEcCtD
Nebivolol—ADRB2—Signaling Pathways—WWOX—esophageal cancer	0.00135	0.00157	CbGpPWpGaD
Nebivolol—Shock—Capecitabine—esophageal cancer	0.00133	0.00951	CcSEcCtD
Nebivolol—HTR1A—GPCR downstream signaling—CXCL2—esophageal cancer	0.00133	0.00155	CbGpPWpGaD
Nebivolol—Nervous system disorder—Capecitabine—esophageal cancer	0.00133	0.00948	CcSEcCtD
Nebivolol—Thrombocytopenia—Capecitabine—esophageal cancer	0.00133	0.00947	CcSEcCtD
Nebivolol—HTR1A—Signaling Pathways—WWOX—esophageal cancer	0.00132	0.00154	CbGpPWpGaD
Nebivolol—Asthenia—Cisplatin—esophageal cancer	0.00132	0.00941	CcSEcCtD
Nebivolol—Cardiac disorder—Methotrexate—esophageal cancer	0.00132	0.0094	CcSEcCtD
Nebivolol—Skin disorder—Capecitabine—esophageal cancer	0.00131	0.00939	CcSEcCtD
Nebivolol—ADRB1—Signaling Pathways—FKBP1A—esophageal cancer	0.00131	0.00153	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—ANXA1—esophageal cancer	0.00129	0.0015	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—FKBP1A—esophageal cancer	0.00129	0.0015	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—WIF1—esophageal cancer	0.00128	0.00149	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—ANXA1—esophageal cancer	0.00127	0.00147	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—CXCL2—esophageal cancer	0.00126	0.00147	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—SST—esophageal cancer	0.00126	0.00146	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—FKBP1A—esophageal cancer	0.00126	0.00146	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—WIF1—esophageal cancer	0.00126	0.00146	CbGpPWpGaD
Nebivolol—Diarrhoea—Cisplatin—esophageal cancer	0.00126	0.00897	CcSEcCtD
Nebivolol—Mental disorder—Methotrexate—esophageal cancer	0.00124	0.00887	CcSEcCtD
Nebivolol—HTR1A—GPCR downstream signaling—ANXA1—esophageal cancer	0.00124	0.00144	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—CXCL2—esophageal cancer	0.00124	0.00144	CbGpPWpGaD
Nebivolol—Malnutrition—Methotrexate—esophageal cancer	0.00123	0.00882	CcSEcCtD
Nebivolol—ADRB2—GPCR downstream signaling—SST—esophageal cancer	0.00123	0.00143	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—WIF1—esophageal cancer	0.00123	0.00143	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—GHRL—esophageal cancer	0.00123	0.00143	CbGpPWpGaD
Nebivolol—Insomnia—Capecitabine—esophageal cancer	0.00122	0.00874	CcSEcCtD
Nebivolol—Paraesthesia—Capecitabine—esophageal cancer	0.00122	0.00868	CcSEcCtD
Nebivolol—HTR1A—Signaling by GPCR—CXCL2—esophageal cancer	0.00121	0.00141	CbGpPWpGaD
Nebivolol—Dyspnoea—Capecitabine—esophageal cancer	0.00121	0.00862	CcSEcCtD
Nebivolol—HTR1A—GPCR downstream signaling—SST—esophageal cancer	0.0012	0.0014	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—GHRL—esophageal cancer	0.0012	0.00139	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CSNK1A1—esophageal cancer	0.00119	0.00138	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—ANXA1—esophageal cancer	0.00117	0.00137	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—GHRL—esophageal cancer	0.00117	0.00136	CbGpPWpGaD
Nebivolol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00117	0.00835	CcSEcCtD
Nebivolol—Vomiting—Cisplatin—esophageal cancer	0.00117	0.00834	CcSEcCtD
Nebivolol—Fatigue—Capecitabine—esophageal cancer	0.00117	0.00833	CcSEcCtD
Nebivolol—ADRB2—Signaling Pathways—CSNK1A1—esophageal cancer	0.00116	0.00135	CbGpPWpGaD
Nebivolol—Rash—Cisplatin—esophageal cancer	0.00116	0.00827	CcSEcCtD
Nebivolol—Dermatitis—Cisplatin—esophageal cancer	0.00116	0.00826	CcSEcCtD
Nebivolol—ADRB2—Signaling by GPCR—ANXA1—esophageal cancer	0.00115	0.00134	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—SST—esophageal cancer	0.00114	0.00133	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CSNK1A1—esophageal cancer	0.00113	0.00132	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—ANXA1—esophageal cancer	0.00112	0.00131	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—SST—esophageal cancer	0.00112	0.0013	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—GHRL—esophageal cancer	0.00111	0.00129	CbGpPWpGaD
Nebivolol—Vertigo—Methotrexate—esophageal cancer	0.00111	0.00792	CcSEcCtD
Nebivolol—ADRB1—Signaling Pathways—PFN1—esophageal cancer	0.00111	0.00129	CbGpPWpGaD
Nebivolol—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00111	0.0079	CcSEcCtD
Nebivolol—HTR1A—Signaling by GPCR—SST—esophageal cancer	0.00109	0.00127	CbGpPWpGaD
Nebivolol—Nausea—Cisplatin—esophageal cancer	0.00109	0.00779	CcSEcCtD
Nebivolol—ADRB2—Signaling by GPCR—GHRL—esophageal cancer	0.00109	0.00127	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PFN1—esophageal cancer	0.00108	0.00126	CbGpPWpGaD
Nebivolol—Urticaria—Capecitabine—esophageal cancer	0.00108	0.00768	CcSEcCtD
Nebivolol—Abdominal pain—Capecitabine—esophageal cancer	0.00107	0.00764	CcSEcCtD
Nebivolol—HTR1A—Signaling by GPCR—GHRL—esophageal cancer	0.00106	0.00124	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PFN1—esophageal cancer	0.00106	0.00123	CbGpPWpGaD
Nebivolol—Chest pain—Methotrexate—esophageal cancer	0.00105	0.00751	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00104	0.00746	CcSEcCtD
Nebivolol—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.00104	0.00121	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.00104	0.00121	CbGpPWpGaD
Nebivolol—Hypersensitivity—Capecitabine—esophageal cancer	0.000997	0.00712	CcSEcCtD
Nebivolol—ADRB1—Signaling Pathways—ELMO1—esophageal cancer	0.000996	0.00116	CbGpPWpGaD
Nebivolol—Nervous system disorder—Methotrexate—esophageal cancer	0.000988	0.00706	CcSEcCtD
Nebivolol—Thrombocytopenia—Methotrexate—esophageal cancer	0.000986	0.00705	CcSEcCtD
Nebivolol—Skin disorder—Methotrexate—esophageal cancer	0.000979	0.00699	CcSEcCtD
Nebivolol—ADRB2—Signaling Pathways—ELMO1—esophageal cancer	0.000975	0.00113	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—AKAP13—esophageal cancer	0.000974	0.00113	CbGpPWpGaD
Nebivolol—Asthenia—Capecitabine—esophageal cancer	0.000971	0.00694	CcSEcCtD
Nebivolol—Pruritus—Capecitabine—esophageal cancer	0.000957	0.00684	CcSEcCtD
Nebivolol—HTR1A—Signaling Pathways—ELMO1—esophageal cancer	0.000953	0.00111	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—AKAP13—esophageal cancer	0.000952	0.00111	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—AKAP13—esophageal cancer	0.000931	0.00108	CbGpPWpGaD
Nebivolol—Diarrhoea—Capecitabine—esophageal cancer	0.000926	0.00661	CcSEcCtD
Nebivolol—Insomnia—Methotrexate—esophageal cancer	0.000911	0.00651	CcSEcCtD
Nebivolol—Paraesthesia—Methotrexate—esophageal cancer	0.000905	0.00646	CcSEcCtD
Nebivolol—ADRB1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000899	0.00104	CbGpPWpGaD
Nebivolol—Dyspnoea—Methotrexate—esophageal cancer	0.000898	0.00642	CcSEcCtD
Nebivolol—Somnolence—Methotrexate—esophageal cancer	0.000896	0.0064	CcSEcCtD
Nebivolol—Dizziness—Capecitabine—esophageal cancer	0.000895	0.00639	CcSEcCtD
Nebivolol—ADRB1—Signaling Pathways—PDE4D—esophageal cancer	0.000891	0.00104	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CA1—esophageal cancer	0.000885	0.00103	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000885	0.00103	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000879	0.00102	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PDE4D—esophageal cancer	0.000871	0.00101	CbGpPWpGaD
Nebivolol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00087	0.00621	CcSEcCtD
Nebivolol—Fatigue—Methotrexate—esophageal cancer	0.000869	0.0062	CcSEcCtD
Nebivolol—Vomiting—Capecitabine—esophageal cancer	0.00086	0.00615	CcSEcCtD
Nebivolol—HTR1A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00086	0.000999	CbGpPWpGaD
Nebivolol—Rash—Capecitabine—esophageal cancer	0.000853	0.0061	CcSEcCtD
Nebivolol—Dermatitis—Capecitabine—esophageal cancer	0.000853	0.00609	CcSEcCtD
Nebivolol—HTR1A—Signaling Pathways—PDE4D—esophageal cancer	0.000852	0.00099	CbGpPWpGaD
Nebivolol—Headache—Capecitabine—esophageal cancer	0.000848	0.00606	CcSEcCtD
Nebivolol—ADRB1—Signaling Pathways—GNG7—esophageal cancer	0.000847	0.000985	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—GNG7—esophageal cancer	0.000829	0.000963	CbGpPWpGaD
Nebivolol—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000824	0.00588	CcSEcCtD
Nebivolol—HTR1A—Signaling Pathways—GNG7—esophageal cancer	0.00081	0.000942	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CA2—esophageal cancer	0.00081	0.000941	CbGpPWpGaD
Nebivolol—Nausea—Capecitabine—esophageal cancer	0.000804	0.00574	CcSEcCtD
Nebivolol—Urticaria—Methotrexate—esophageal cancer	0.0008	0.00572	CcSEcCtD
Nebivolol—Abdominal pain—Methotrexate—esophageal cancer	0.000796	0.00569	CcSEcCtD
Nebivolol—ADRB1—Signaling Pathways—XIAP—esophageal cancer	0.000794	0.000923	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—XIAP—esophageal cancer	0.000776	0.000903	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—XIAP—esophageal cancer	0.000759	0.000883	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000753	0.000875	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000753	0.000875	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CTNNA1—esophageal cancer	0.000751	0.000873	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CXCL2—esophageal cancer	0.000746	0.000868	CbGpPWpGaD
Nebivolol—Hypersensitivity—Methotrexate—esophageal cancer	0.000742	0.0053	CcSEcCtD
Nebivolol—ADRB2—Signaling Pathways—CTNNA1—esophageal cancer	0.000734	0.000854	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CXCL2—esophageal cancer	0.00073	0.000849	CbGpPWpGaD
Nebivolol—Asthenia—Methotrexate—esophageal cancer	0.000723	0.00516	CcSEcCtD
Nebivolol—HTR1A—Signaling Pathways—CTNNA1—esophageal cancer	0.000718	0.000835	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CXCL2—esophageal cancer	0.000714	0.00083	CbGpPWpGaD
Nebivolol—Pruritus—Methotrexate—esophageal cancer	0.000713	0.00509	CcSEcCtD
Nebivolol—ADRB1—Signaling Pathways—PSME1—esophageal cancer	0.000697	0.000811	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PSME2—esophageal cancer	0.000697	0.000811	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—ANXA1—esophageal cancer	0.000694	0.000807	CbGpPWpGaD
Nebivolol—Diarrhoea—Methotrexate—esophageal cancer	0.000689	0.00492	CcSEcCtD
Nebivolol—ADRB2—Signaling Pathways—PSME1—esophageal cancer	0.000682	0.000793	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PSME2—esophageal cancer	0.000682	0.000793	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—ANXA1—esophageal cancer	0.000679	0.000789	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—SST—esophageal cancer	0.000675	0.000785	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PSME1—esophageal cancer	0.000667	0.000775	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PSME2—esophageal cancer	0.000667	0.000775	CbGpPWpGaD
Nebivolol—Dizziness—Methotrexate—esophageal cancer	0.000666	0.00476	CcSEcCtD
Nebivolol—HTR1A—Signaling Pathways—ANXA1—esophageal cancer	0.000664	0.000772	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—SST—esophageal cancer	0.00066	0.000768	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.00066	0.000767	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—GHRL—esophageal cancer	0.000658	0.000765	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—NOTCH3—esophageal cancer	0.000658	0.000765	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—FBXW7—esophageal cancer	0.000647	0.000752	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—SST—esophageal cancer	0.000646	0.000751	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—NOTCH3—esophageal cancer	0.000643	0.000748	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—GHRL—esophageal cancer	0.000643	0.000748	CbGpPWpGaD
Nebivolol—Vomiting—Methotrexate—esophageal cancer	0.000641	0.00458	CcSEcCtD
Nebivolol—Rash—Methotrexate—esophageal cancer	0.000635	0.00454	CcSEcCtD
Nebivolol—Dermatitis—Methotrexate—esophageal cancer	0.000635	0.00453	CcSEcCtD
Nebivolol—ADRB2—Signaling Pathways—FBXW7—esophageal cancer	0.000633	0.000736	CbGpPWpGaD
Nebivolol—Headache—Methotrexate—esophageal cancer	0.000631	0.00451	CcSEcCtD
Nebivolol—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000631	0.000733	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—NOTCH3—esophageal cancer	0.000629	0.000732	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—GHRL—esophageal cancer	0.000629	0.000732	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—FBXW7—esophageal cancer	0.000619	0.00072	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000614	0.000713	CbGpPWpGaD
Nebivolol—Nausea—Methotrexate—esophageal cancer	0.000598	0.00427	CcSEcCtD
Nebivolol—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000598	0.000695	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—NOTCH2—esophageal cancer	0.00059	0.000686	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—NOTCH2—esophageal cancer	0.000577	0.000671	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—TPI1—esophageal cancer	0.00057	0.000663	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.00057	0.000663	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—NOTCH2—esophageal cancer	0.000564	0.000656	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000547	0.000636	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000526	0.000612	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TGFBR2—esophageal cancer	0.000523	0.000609	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000522	0.000607	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TGFBR2—esophageal cancer	0.000512	0.000595	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TGFBR2—esophageal cancer	0.000501	0.000582	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000496	0.000577	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—SMAD4—esophageal cancer	0.000495	0.000576	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—SMAD4—esophageal cancer	0.000485	0.000563	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—SMAD4—esophageal cancer	0.000474	0.000551	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000465	0.000541	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.000442	0.000514	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.000437	0.000508	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.000414	0.000482	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ENO1—esophageal cancer	0.000414	0.000482	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PSME1—esophageal cancer	0.000408	0.000475	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PSME2—esophageal cancer	0.000408	0.000475	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	0.000405	0.000471	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	0.000396	0.000461	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	0.000388	0.000451	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—KDR—esophageal cancer	0.000388	0.000451	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—KDR—esophageal cancer	0.000379	0.000441	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—KDR—esophageal cancer	0.000371	0.000431	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	0.000365	0.000425	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	0.000357	0.000415	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP1B1—esophageal cancer	0.000352	0.00041	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	0.000349	0.000406	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CYP19A1—esophageal cancer	0.000331	0.000385	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	0.000331	0.000385	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	0.000325	0.000378	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	0.000324	0.000377	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	0.000318	0.00037	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	0.000317	0.000368	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	0.000311	0.000362	CbGpPWpGaD
Nebivolol—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000311	0.000362	CbGpPWpGaD
Nebivolol—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000304	0.000354	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—HMOX1—esophageal cancer	0.000302	0.000352	CbGpPWpGaD
Nebivolol—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000297	0.000346	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—NOS3—esophageal cancer	0.000296	0.000345	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—ABCB1—esophageal cancer	0.00029	0.000337	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—NOS3—esophageal cancer	0.00029	0.000337	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—NOS3—esophageal cancer	0.000284	0.00033	CbGpPWpGaD
Nebivolol—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	0.000282	0.000328	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	0.000277	0.000322	CbGpPWpGaD
Nebivolol—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	0.000276	0.000321	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	0.000271	0.000315	CbGpPWpGaD
Nebivolol—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	0.00027	0.000314	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	0.000265	0.000308	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CCND1—esophageal cancer	0.000245	0.000285	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CCND1—esophageal cancer	0.00024	0.000279	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	0.000237	0.000276	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CCND1—esophageal cancer	0.000234	0.000272	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	0.000232	0.00027	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	0.000227	0.000264	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—EP300—esophageal cancer	0.000225	0.000262	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—EP300—esophageal cancer	0.000221	0.000256	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—EP300—esophageal cancer	0.000216	0.000251	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—MYC—esophageal cancer	0.000196	0.000228	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—CREBBP—esophageal cancer	0.000194	0.000226	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—MYC—esophageal cancer	0.000192	0.000223	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—EGFR—esophageal cancer	0.000192	0.000223	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—EGFR—esophageal cancer	0.000188	0.000219	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—MYC—esophageal cancer	0.000188	0.000219	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—EGFR—esophageal cancer	0.000184	0.000214	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—NOS3—esophageal cancer	0.000174	0.000202	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	0.000167	0.000194	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	0.000163	0.00019	CbGpPWpGaD
Nebivolol—ADRB1—Signaling Pathways—TP53—esophageal cancer	0.000161	0.000188	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	0.00016	0.000186	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PTGS2—esophageal cancer	0.000159	0.000185	CbGpPWpGaD
Nebivolol—ADRB2—Signaling Pathways—TP53—esophageal cancer	0.000158	0.000184	CbGpPWpGaD
Nebivolol—HTR1A—Signaling Pathways—TP53—esophageal cancer	0.000154	0.000179	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—EP300—esophageal cancer	0.000132	0.000154	CbGpPWpGaD
Nebivolol—CYP2D6—Metabolism—PIK3CA—esophageal cancer	9.77e-05	0.000114	CbGpPWpGaD
